Alphadyne Asset Management LP
Position in VRTX — Vertex Pharmaceuticals Inc / Ma
CIK 1535943
NEW YORK, NY
Position in VRTX
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$36,261
-$3,947,768 QoQ
Shares Held
73
-99.2% QoQ
Ownership
0.000%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#1,557
of 1,742 holders
Holding Since
Dec 2025
3 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in VRTX Over Time
Shares Held
Position Value (USD)
Derivatives in VRTX
reported options exposure · as of Jun 30, 2026CallValue
$1,142,479
CallShares
2,300
PutValue
$3,576,456
PutShares
7,200
Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.
Position in Biotechnology
Healthcare · as of Jun 30, 2026Alphadyne Asset Management LP holds $66,190 across 2 Biotechnology names. VRTX ranks #1 (54.8% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | VRTX |
Vertex Pharmaceuticals Inc / Ma
This page
|
73 | $36,261 | |
| 2 | REGN |
Regeneron Pharmaceuticals, Inc.
|
48 | $29,929 |
All Filings in VRTX
Export CSV
8 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $36,261 | 73 | Shares | Sole | 2026-08-14 | |
| 2026-06-30 | $1,142,479 | 2,300 | Call | Sole | 2026-08-14 | |
| 2026-06-30 | $3,576,456 | 7,200 | Put | Sole | 2026-08-14 | |
| 2026-03-31 | $6,564,138 | 14,700 | Call | Sole | 2026-05-15 | |
| 2026-03-31 | $10,091,804 | 22,600 | Put | Sole | 2026-05-15 | |
| 2026-03-31 | $3,984,029 | 8,922 | Shares | Sole | 2026-05-15 | |
| 2025-12-31 | $906,720 | 2,000 | Put | Sole | 2026-02-17 | |
| 2025-12-31 | $906,720 | 2,000 | Call | Sole | 2026-02-17 | |
| No filing history on record for this holder in this stock. | ||||||